TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Visual changes of atypical nevi: size, border, color
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cellular changes of the atypical nevi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: number of complete surgical procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Assess safety changes in electrocardiogram (ECG)
Endpoint domain: Adverse events/effects
Primary endpoint: Assess safety changes of body weight
Endpoint domain: Adverse events/effects
Primary endpoint: Ischemia-driven target lesion failure (iTLF)
Endpoint domain: Mortality/survival
Primary endpoint: Target vessel related myocardial infarction (MI)
Endpoint domain: Mortality/survival
Primary endpoint: Ischemic-driven target lesion revascularization (iTLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Preservation of beta cells function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total Amount of Canine Retraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of glycemic events outside the serum glucose range of 110-150 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Biochemical testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean body weight at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hearing improvement or stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and Types of Additional Tools Required to Mobilize the Liver During Procedure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants With Adverse Events and Device Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with normal left ventricular end diastolic dimension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quantification of the immune cell subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Transcriptional Immune cell profiling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Major Structural Birth Defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marijuana Self-administration - Progressive Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marijuana Self-administration - Drug Vs Money Choice
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma selenoprotein P
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma GPX-3 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total plasma selenium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tinel's Sign
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of ETC-1922159
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended Dose (RD) of ETC-1922159
Endpoint domain: Adverse events/effects
Primary endpoint: Change-score of PsASon22
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change-score of PsASon13
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Migraines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of Migraines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Migraine Duration, in Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pediatric Migraine Disability Score (PedMIDAS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Participants Receiving HPV Vaccination (Dose 1)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With Any Serious and/or Non-Serious Grades 3, 4, and/or 5 Adverse Events Due to Drug
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Response at 24 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral food intolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of New Surgically Eligible Basal-cell Carcinomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Score on the feasibility questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Game Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in the Box and Block Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endothelial function markers (CD31, CD41, CD34)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI Bold signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of temperature decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Associate the development of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercised Induced Fatigability
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Immunological success (CD4 cell count above 200 cells/mm3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adherence to prescribed exercise program
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clinically significant bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the ROC curve (AUC) of the variation of the pulsed pressure (VPP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of adoptive transfer of gene-modified autologous CD19-specific T cells
Endpoint domain: Adverse events/effects
Primary endpoint: Major Cardiovascular Disease Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy of polyp characterisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Vestibular Ocular Reflex (VOR) amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in pure tone audiometry measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in gait dynamics while walking at different speeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return of hormones produced by the ovarian tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: cervical lymph node metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement in Quantitative Serum HDV RNA Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in fibromyalgia symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average and worst pain during the last 24 hours
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: AECOPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: heart failure (AHF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Lymphoma long-term survivors
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients who recovered
Endpoint domain: Mortality/survival
Primary endpoint: Urinary metabolic ratio Dextromethorphan/Dextrorphan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of an episode of Axis 1 mood disorder
Endpoint domain: Adverse events/effects
Primary endpoint: Size of Retinal Astrocytic Hamartomas compared to baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of retinal exudate compared to baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal detachment progression/regression compared to baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum levels of Progranulin (PGRN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum levels of soluble tumor necrosis factor receptor 1 (sTNFR1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum levels of Neutrophil gelatinase-associated lipocalin (NGAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum levels of cystatin C (Cys-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Expression of U19 Gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tremor Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Feasibility of identification of primary nodal drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety of identification of primary nodal drainage
Endpoint domain: Adverse events/effects
Primary endpoint: Recovery of gastro-intestinal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Survivorship of Components
Endpoint domain: Mortality/survival
Primary endpoint: Maternal post-natal depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: pain score 12 hours postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life according to NCCN-FACT FKSI-19
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Perceived support in decision-making
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum Concentrations Level (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Concentration Level (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination Half-life (t ½)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients without clinically relevant cerebrospinal fluid (CSF) leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Breast volume measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in titrated nasal provocation test (TNPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of participants using drug resistance strategies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inflammation level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: nutrition condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: cardio pulmonary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: diabetes distress (DDS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of peak systolic blood flow velocity in the common carotid arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of end-diastolic blood flow velocity in the common carotid arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of diastolic and systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of peak systolic blood flow velocity in the internal carotid arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of end-diastolic blood flow velocity in the internal carotid arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of complete resections without recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of infection with or without delta-haemolysin in Staphylococcus Aureus
Endpoint domain: Adverse events/effects
Primary endpoint: Non-Surgical Resolution of Vitreomacular Adhesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Change in Blood Serum Levels of Bupivocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: pre-prandial fMRI-FCR changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-prandial fMRI-FCR changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: energy intake changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: hunger/satiety changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pharmacokinetic parameters of imeglimin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Progesterone Concentration Not Less Than 10 ng/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Venous engorgement/beading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Change in parameters that reflect a hypoxic state assessed by pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in parameters that reflect a hypoxic state assessed by pO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in parameters that reflect a hypoxic state assessed by pCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in parameters that reflect a hypoxic state assessed by Lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in parameters that reflect an inflammatory reaction assessed by WBCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Variation of ASDAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inner luminal area change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Femur health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean Change in Low Density Lipoprotein (LDL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Endothelial Function as Measured on MRI in the Arms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Endothelial Function as Measured on MRI in the Legs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sum of attack durations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAPS-5 Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of grey/white matter volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage Of Participants With An Increase In Hemoglobin ≥1.0 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: clinical pregnancy per women randomized
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: change in overall cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: changes in norepinephrine requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: BDM Score Change From Baseline at Day 42
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radioactivity concentration in urine, feces and dialysate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radioactivity concentration in whole blood and plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endo-sinus bone gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of study drug (MK-0683)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intradermal Tuberculin Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: QuantiFERON TB Gold In-Tube®
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: T-SPOT.TB®
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Env-specific IgG binding response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Toxicity rate of DLTs
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of pembrolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) at Day 30 Post 12-Month Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Who Achieved Antibody Titers >=1:8 by hSBA at Day 30 Post 6-Month Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: rate of patients with complete asparagine depletion in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal weight gain in pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight of the newborn
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal fasting serum glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of operative delivery, both cesarean section and operative vaginal delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maternal body composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Number of Participants With Negative Chlamydia DFA Test Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With One or More Treatment Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Serum morphine concentration level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pacemaker implantation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pain on Movement on Day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of severe secondary PPH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Stroop Test Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Levels of RANKL in crevicular fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of OPG in crevicular fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ferritin levels at 61 days of life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of infants fulfilling criteria of ID
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: venous blood total antioxidant capacity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Agreement Rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: glycosylated hemoglobin (GHb)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recovery Assessment Scale - Revised
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence rate of fibrosing colonopathy
Endpoint domain: Adverse events/effects
Primary endpoint: Patient Medication Adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Electrochemical conductance (µS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medical exam results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Lesion Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Renal Function Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Lung function tests (residual volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: intracranial local tumor control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: QT/QTc interval prolongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite unscheduled acute health care resource utilisation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Subjective postoperative de novo stress urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Lower Extremity Amputation
Endpoint domain: Adverse events/effects
Primary endpoint: Amputation-free Survival
Endpoint domain: Mortality/survival